# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Paul Robeson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML048-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Theodore Bankole-Ashworth, MD
- Calendar frame: modern shifted

## What we are working on

- He is exhausted, sleeps poorly and has lost the wish to sing, and wants to know what is wrong **S**
- He worries that a psychiatric record could be used against him by the people who have taken his passport and his work **S**
- He wants to keep working for civil rights and to sing again **S**

## Your goals

- Response to treatment: PHQ-9 down by at least half from 22. Target: 2026-10-05. Recorded outcome: PHQ-9 6 at about seven months, a 73 percent fall. **S**
- Remission: PHQ-9 below 5. Target: 2026-10-05. Recorded outcome: Not yet met: PHQ-9 6 six weeks after augmentation; continuing. **S**
- Stay safe: safety plan in place and reviewed at every visit, with no self-harm. Target: 2026-10-05. Recorded outcome: Met so far: no thoughts of suicide since the first months; safety plan reviewed at every visit. **S**
- Sing again: daily vocal practice and one public engagement a month. Target: 2026-10-05. Recorded outcome: Daily practice resumed; sang at two community gatherings in the past month. **S**
- Sleep six to seven hours a night. Target: 2026-10-05. Recorded outcome: About six and a half hours a night. **S**

## What we agreed to do

- Evaluation: PHQ-9, GAD-7, AUDIT-C and a cognitive screen (MoCA); blood count, metabolic panel, calcium, TSH, vitamin B12, folate, morning testosterone and hemoglobin A1c, with HIV and syphilis tests, to exclude medical causes; a review of medicines; and a sleep apnea screen. Guideline: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Urgent psychiatric consultation in three days to confirm the diagnosis with a structured interview, screen for bipolar disorder, judge suicide risk and the level of care, and advise on psychotherapy, medicines, and when ECT or other treatments would be indicated. Guideline: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001) **S**
- Safety: structured suicide-risk assessment, a written safety plan, no firearm in the home, medicines dispensed in limited supplies and kept locked, the 988 Suicide & Crisis Lifeline, and a safety review at every visit. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
- Trust and equity: explain who can see his record and how it is protected; a therapist of his choosing, including a Black clinician if he wishes; treat discrimination and persecution as real stressors and record his account of surveillance as realistic; a social worker for help with income and costs; guard against the documented under-treatment of depression in Black patients by measuring response at every visit. Guideline: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007); Sprenger S, et al. Retrospective Cohort Study of Racial-Ethnic Disparities in Receipt of Electroconvulsive Therapy, 2016-2021. Psychiatr Serv 2025;76(8):736-740 (2025); Racial disparities in psychotic disorder diagnosis: A review of empirical literature (2014) **S**
- Treatment: behavioral activation weekly with a psychologist for about sixteen sessions, then CBT if needed; sertraline 50 mg, raised to 100 mg at two weeks and to 200 mg by eight weeks as tolerated; PHQ-9 at every visit with response defined as a 50 percent fall and remission as a score below 5; sodium at about six weeks; switch to an SNRI if the PHQ-9 falls by less than a quarter after an adequate trial, and consider augmentation, ECT, rTMS or esketamine if a second adequate trial brings only a partial response; watch for hypomania after starting an antidepressant. Guideline: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Switch to venlafaxine extended-release by cross-taper: venlafaxine 75 mg for a week while sertraline is halved, then 150 mg for three weeks and 225 mg; blood pressure at every visit; 30-day supplies because venlafaxine is more dangerous in overdose. Guideline: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022) **S**
- Treatment-resistant depression: aripiprazole 2 mg, raised to 5 mg at two weeks, with weight at four, eight and twelve weeks, A1c and lipids at baseline and twelve weeks, and an abnormal involuntary movement examination at baseline and six months; an informed consent discussion about ECT (general anesthesia with a muscle relaxant, right unilateral ultrabrief pulse, two or three treatments a week in a defined course, cognitive testing before and during the course, and the right to stop at any time), with rTMS and esketamine as alternatives; ECT not started now and offered if augmentation fails or if he becomes unable to eat or drink, psychotic or acutely suicidal. Guideline: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 3rd edition (Library of Congress catalog record, LCCN 2024014438) (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Sprenger S, et al. Retrospective Cohort Study of Racial-Ethnic Disparities in Receipt of Electroconvulsive Therapy, 2016-2021. Psychiatr Serv 2025;76(8):736-740 (2025) **S**
- Acute bronchitis: no antibiotic and no chest X-ray with normal vital signs and a normal chest examination; honey, warm drinks and steam; plain guaifenesin if needed; no dextromethorphan, which with venlafaxine can cause serotonin syndrome, and no pseudoephedrine or phenylephrine, which raise blood pressure further on venlafaxine; check labels of combination cold remedies; return for fever, breathlessness, chest pain or a cough lasting more than three weeks. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention (2016) **S**
- Prevention: stool FIT kit for colorectal screening; the earlier prostate surgery records obtained before any decision on PSA testing; a ten-year cardiovascular risk of about 9 percent discussed, with his choice of diet and activity first and a statin to be reconsidered in a year; hepatitis B and C screening; influenza, PCV20 and the first recombinant zoster dose today, the second zoster dose in two to six months. Guideline: Colorectal Cancer: Screening (2021); Prostate Cancer: Screening (2018); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026) **S**

## Follow-up

- 2026-03-09: New patient visit for three months of low mood, exhaustion, poor sleep and withdrawal: depression screening, safety assessment and safety plan, tests for medical causes, and urgent psychiatric consultation **S**
- 2026-03-12: Psychiatric consultation and review: diagnosis of recurrent major depression, bipolar screening, start of sertraline and behavioral activation **S**
- 2026-04-20: Six-week review: minimal response; sertraline increased **S**
- 2026-06-08: Three-month review: no response to an adequate sertraline trial; switch to venlafaxine **S**
- 2026-08-24: Twenty-four-week review: partial response to venlafaxine; treatment-resistant depression; aripiprazole augmentation and an informed consent discussion about ECT **S**
- 2026-10-05: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
